Observational studyBMC infectious diseases2016
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex.
Observational study in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Observational
- Catheter mechanoprophylaxis againstMicrobiology (Reading, England) · 2026Article
- Trends in Candidemia Over the Last 14 Years: A Comparative Analysis ofOpen forum infectious diseases · 2025Article
- Epidemiology and Clinical Features ofJournal of fungi (Basel, Switzerland) · 2025Article
- Molecular and biological characteristics of two rare bloodstream Candida isolates: Candida nonsorbophila and Candida sonorensis.BMC infectious diseases · 2025Article
- Evaluation of the Disinfection Efficacy of Er: YAG Laser Light on Single-Species Candida Biofilms-An In Vitro Study.Dentistry journal · 2025Article
- Good Outcomes After a Severity Triad: Systemic Complications, Bacterial and Fungal Infections in 3 Patients With Major Burns.Eplasty · 2025Article
- Effects ofArchives of Razi Institute · 2024Article
- Exploring the Antibiofilm Effect of Sertraline in Synergy withPharmaceuticals (Basel, Switzerland) · 2024Article
- Candida parapsilosis complex in the clinical setting.Nature reviews. Microbiology · 2024Review
- A Case of Central Venous Catheter-RelatedMediterranean journal of hematology and infectious diseases · 2024Article
- Antifungal Activity of 3-Hydrazinoquinoxaline-2-Thiol, a Novel Quinoxaline Derivative against Candida Species.Mycobiology · 2024Article
- Standardization of polymerase chain reaction for detection of fluconazole resistance targeting Y132F mutation inCurrent medical mycology · 2024Article
- Racial disparities among candidemic patients at a Southern California teaching hospital.Infection control and hospital epidemiology · 2023Article
- Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap.The Lancet. Microbe · 2023Review
- Epidemiologic features, clinical characteristics, and predictors of mortality in patients with candidemia in Alameda County, California; a 2017-2020 retrospective analysis.BMC infectious diseases · 2022Article
- cleanSURFACESFrontiers in cellular and infection microbiology · 2022Article
- The Antibacterial Synthetic Flavonoid BrCl-Flav Exhibits Important Anti-Pharmaceuticals (Basel, Switzerland) · 2021Article
- Role of Antifungal Combinations in Difficult to TreatJournal of fungi (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough Candida albicans is the most common cause of fungal blood stream infections (BSIs), infections due to Candida species other than C. albicans are rising. Candida parapsilosis complex has emerged as an important fungal pathogen and became one of the main causes of fungemia in specific geographical areas. We analyzed the factors related to outcome of candidemia due to C. parapsilosis in a single tertiary referral hospital over a five-year period.
methodsA retrospective observational study of all cases of candidemia was carried out at a 980-bedded University Hospital in Italy. Data regarding demographic characteristics and clinical risk factors were collected from the patient's medical records. Antifungal susceptibility testing was performed and MIC results were interpreted according to CLSI species-specific clinical breakpoints.
resultsOf 270 patients diagnosed with Candida BSIs during the study period, 63 (23 %) were infected with isolates of C. parapsilosis complex which represented the second most frequently isolated yeast after C. albicans. The overall incidence rate was 0.4 episodes/1000 hospital admissions. All the strains were in vitro susceptible to all antifungal agents. The overall crude mortality at 30 days was 27 % (17/63), which was significantly lower than that reported for C. albicans BSIs (42 % [61/146], p = 0.042). Being hospitalized in ICU resulted independently associated with a significant higher risk of mortality (HR 4.625 [CI95% 1.015-21.080], p = 0.048). Conversely, early CVC removal was confirmed to be significantly associated with a lower risk of mortality (HR 0.299 [CI95% 0.102-0.874], p = 0.027). Finally, the type of primary antifungal therapy did not influence the outcome of infection.
conclusionsCandidemia due to C. parapsilosis complex, the second most commonly causative agent of yeast BSIs in our center, is characterized by a non-negligible mortality at 30 days. An early CVC removal is associated with a significant reduced mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.